A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Etoposide
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMpower133
- Sponsors Chugai Pharmaceutical; Roche
- 03 Jul 2017 Planned End Date changed from 31 Jul 2019 to 1 Aug 2019.
- 03 Jul 2017 Planned primary completion date changed from 31 Jul 2019 to 1 Aug 2019.
- 08 Jun 2017 Planned number of patients changed from 400 to 500.